Sarc
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
- Conditions
- HLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS)
- Interventions
- Drug: Physician's Choice
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Target Recruit Count
- 47
- Registration Number
- NCT06942442
SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
- Conditions
- Gastrointestinal Stromal TumorsGIST
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-01-31
- Target Recruit Count
- 40
- Registration Number
- NCT06208748
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
- Conditions
- Advanced Dedifferentiated Liposarcoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 108
- Registration Number
- NCT04967521
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
- Conditions
- Osteosarcoma in ChildrenOsteosarcoma RecurrentOsteosarcoma MetastaticOsteosarcoma
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-04-18
- Target Recruit Count
- 48
- Registration Number
- NCT04803877
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Cincinnati Children's, Cincinnati, Ohio, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
- Conditions
- Ewing Sarcoma
- Interventions
- Diagnostic Test: tumor biopsyOther: 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2025-04-29
- Target Recruit Count
- 37
- Registration Number
- NCT04067115
- Locations
- 🇺🇸
Boston Children's Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
- Conditions
- Malignant Peripheral Nerve Sheath TumorsNeurofibromatosis 1
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-26
- Target Recruit Count
- 21
- Registration Number
- NCT03433183
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
- Conditions
- Soft Tissue Sarcoma of the Extremity
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 126
- Registration Number
- NCT03092323
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Mayo Clinic- Florida, Jacksonville, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
SARC021C: A Continuation Study of TH-CR-406/SARC021
- Conditions
- Soft Tissue Sarcoma
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-01-29
- Target Recruit Count
- 20
- Registration Number
- NCT02303262
- Locations
- 🇺🇸
Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Ohio State University, Columbus, Ohio, United States